Feed ADTX
AD

Aditxt, Inc.

ADTX · OTC

$0.00 +4.44% (+$0.00)
1M -20.69%
Market Cap $4.57M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$0.01

112.8% upside

Trenutna cena

$0.0047

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ADTX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 318.48x
P/E N/A
EV/EBITDA N/A
Growth
8 /100
Declining
Rev. growth 84.93%
Book val. growth 2.52%
EPS growth N/A
Profitability
6 /100
Weak
Gross margin 19.89%
Net margin 362,386.00%
Op. margin 127,821.00%
Quality
0 /100
Poor
ROIC 406.31%
ROA 373.57%
Asset turnover 0.00x
Debt
0 /100
High
Current ratio 0.06x
Int. coverage -24.47x
Debt/Equity N/A
Stability
44 /100
Moderate
Beta 0.93x
Rev. volatility 34.46%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ADTX
Online

O podjetju

Aditxt, Inc. (ADTX) is a biotechnology company specializing in the development of innovative therapeutic and diagnostic technologies in the fields of immunology and biomedicine. The company focuses on developing products that can enhance patients' immune systems and improve their health. Aditxt develops diagnostic tools that allow for precise monitoring of immune responses and patients' health status. With the growing emphasis on personalized medicine and advanced diagnostic technologies, Aditxt, Inc. has the potential for sustained growth. Aditxt, Inc. (ADTX) shares might be an interesting choice for investors seeking involvement in the biotechnology and innovative diagnostic therapies industry.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeffrey Busch

Employees

26

Headquarters

Mountain View

Prihajajoči dogodki

02 DEC.

Earnings

Upcoming earnings report

67d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.